BridgeBio Oncology Therapeutics (BBOT) Non-Current Assets (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Non-Current Assets of $151.1 million for Q1 2026, up 845.54% sequentially from $16.0 million in Q4 2025, and down 22.27% YoY from $194.4 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Non-Current Assets (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Non-Current Assets for 3 years, with the latest figure at $151.1 million in Q1 2026.
- Quarterly Non-Current Assets fell 22.27% year-over-year to $151.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $372.4 million (down 35.58% YoY) and the FY2025 annual result came in at $16.0 million, up 185.04% from the prior year.
- Non-Current Assets rose to $151.1 million in Q1 2026 per BBOT's latest filing, from $16.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $196.5 million in Q2 2025 and troughed at $5.6 million in Q4 2024.
- A 3-year average of $126.2 million and a median of $185.4 million in 2024 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 185.04% in 2025, down 95.38% in 2025.
- Over 3 years, Non-Current Assets stood at $5.6 million in 2024, then soared by 185.04% to $16.0 million in 2025, then jumped by 845.54% to $151.1 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $151.1 million, $16.0 million, and $8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 134.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134.33 Mn |
| Mar 31, 2026 | 151.14 Mn |
| Dec 31, 2025 | 15.99 Mn |
| Sep 30, 2025 | 8.78 Mn |
| Jun 30, 2025 | 196.51 Mn |
| Mar 31, 2025 | 194.44 Mn |
| Dec 31, 2024 | 5.61 Mn |
| Sep 30, 2024 | 190.29 Mn |
| Jun 30, 2024 | 187.80 Mn |
| Mar 31, 2024 | 185.42 Mn |